Catalent Inc (0C8.BE)
| Previous Close | 51.94 |
| Open | 52.38 |
| Bid | 52.42 x 0 |
| Ask | 52.59 x 0 |
| Day's Range | 52.38 - 52.38 |
| 52 Week Range | 29.10 - 55.50 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
US FTC seeks more information on Novo Nordisk parent-Catalent deal
Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.
- Reuters
UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. FTC has sought more information on Novo Nordisk parent's $16.5 billion bid for contract drug manufacturer Catalent, weeks after an application to the regulator was refiled for approval of the deal. Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.
- Insider Monkey
How Novo-Catalent Deal Affects Halozyme (HALO)?
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
